NUWE Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 -35.03%, SMA50 -29.6%, SMA200 -79.58%). The stock’s 14-day RSI is 35.59 (weak momentum), while the ATR of 0.33 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -97.16% below its high and over 0.0% above its low. Average 10-day trading volume of 15.93 million shares is significantly above the 3-month average of 2.19 million, indicating heightened recent market interest.

Nuwellis, Inc. generated EPS of -$107.66 over the past year. Five-year average earnings growth is 90.39%. Wall Street analysts project EPS growth of 85.85% annually over the next five years. The latest quarter delivered EPS of -$2.09. The next quarter is forecast at -$1.56. Next year's EPS is expected at $68.03. Nuwellis, Inc. earnings surprise history is a mixed track record. The quarter that ended May 12, 2026, missed forecasts by 109.0%. The prior quarter beat by -3.85%. Over the last six quarters, Apple has recorded several small beats. These include 51.16% in March 11, 2025.

Nuwellis, Inc. (NASDAQ:NUWE) closed at $1.74 USD, losing -$2.71 (-60.90%) from the previous close of $4.45. The stock is currently mid-range between its 52-week high and low $1.61 and $336.00. With a market capitalization of about $633.87 thousand, Nuwellis, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.30). Key stats such as the average daily volume over the past year has been around 2.20 million shares, trading with heavier-than-usual volume. Headquartered in Eden Prairie, MN, Nuwellis, Inc. operates in the Healthcare sector and the Medical - Devices industry. Led by CEO Michael McCormick, the company employs approximately 38 people and listed since February 16, 2012. Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy.

Nuwellis, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.78. This means the shares are trading below this model’s fair value.

Nuwellis, Inc. has 92.20 thousand shares outstanding. The public float is 60.18 thousand shares, elevated short interest at 31.34% of float. This equals 114.18 thousand shares. The short ratio is 0.6 days. Institutional investors hold 1.66% of the float. Insiders own 0.01%. Choi Ki Yong holds 1.79 million shares, BUCKMAN PAUL has 24.01 thousand shares and MATHIESEN JEFFREY S has 20.02 thousand shares.

Nuwellis, Inc. trades at a P/E ratio of -0.0, slightly below the S&P 500 average, with a price-to-sales ratio of 0.07 and a price-to-book ratio of 0.04 suggesting the stock is closer to book value. The P/FCF stands at -0.06, also above market averages.

Our AI price prediction model suggests that Nuwellis, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -45.62%, with price expected at $2.42 by August 13, 2026, within a range of $1.80 to $3.00 3-Month Outlook: Projected fall of -35.06%, reaching $2.89 by October 28, 2026, with a range of $0.00 to $26.25. 1-Year Outlook: Projected loss of -7.64%, with price at $4.11 by July 30, 2027, within a range of $0.00 to $550.71.

Nuwellis, Inc. (NASDAQ:NUWE) shares are flat 5.17% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Nuwellis, Inc. trading at a premium to the broader market with a P/E of -0.0. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $17.00, suggesting 282.02% upside. Our AI forecast model points to short-term weakness (-45.62% over two weeks), a medium-term fall (-35.06% over three months), and a longer-term loss (-7.64% over one year), with expected trading ranges indicating moderate volatility.